Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery

被引:15
作者
Paik, E. Sun [1 ]
Lee, Yoo-Young [1 ]
Shim, Minhee [1 ]
Choi, Hyun Jin [1 ]
Kim, Tae-Joong [1 ]
Choi, Chel Hun [1 ]
Lee, Jeong-Won [1 ]
Kim, Byoung-Gie [1 ]
Bae, Duk-Soo [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Dept Obstet & Gynecol, Samsung Med Ctr, 81 Irwon Ro, Seoul 135710, South Korea
关键词
neoplasms; ovarian neoplasms; prognosis; recurrence; residual; METASTATIC MUCINOUS ADENOCARCINOMAS; CHEMOTHERAPY; SURVIVAL; STATISTICS; PREDICTORS; RESECTION; RISK;
D O I
10.1111/ajo.12529
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveThe aim of this study was to analyse patterns and timing of recurrence and their association with clinical outcomes in recurrent epithelial ovarian cancer (EOC) patients with no gross residual disease after primary debulking surgery (PDS). MethodsThis study was conducted on 303 EOC patients with no residual disease after PDS who were treated at the Samsung Medical Center from 2002 to 2012. By reviewing electronic medical records, information on date of clinical/pathological recurrence and pattern of disease presentation for each relapse were retrieved. ResultsWithin a median follow-up of 53 months (range 3-156), 88 recurrences (29.0%) and 28 cancer-related deaths (9.2%) were observed. Most of the recurrences were distant, discrete and transcoelomic. After complete cytoreduction, the initial stage was associated with location of recurrence, but not with recurrence patterns. Complete cytoreduction reduced the number of recurrences, but it did not affect timing of recurrence. In multivariate analysis for overall survival (OS), patients with distant recurrence, diffuse carcinomatosis and mixed spread pattern of transcoelomic, lymphatic and haematogenous recurrence were found to have higher risk. ConclusionsWe found that timing of recurrence was not affected by complete cytoreduction. Location, type and pattern of recurrence were also significant prognostic factors for OS, in addition to known prognostic predictors such as platinum sensitivity.
引用
收藏
页码:639 / 647
页数:9
相关论文
共 50 条
  • [21] Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery
    Heitz, Florian
    Harter, Philipp
    Alesina, Piero F.
    Walz, Martin K.
    Lorenz, Dietmar
    Groeben, Harald
    Heikaus, Sebastian
    Fisseler-Eckhoff, Anette
    Schneider, Stephanie
    Ataseven, Beyhan
    Kurzeder, Christian
    Prader, Sonia
    Beutel, Bianca
    Traut, Alexander
    du Bois, Andreas
    GYNECOLOGIC ONCOLOGY, 2016, 141 (02) : 264 - 270
  • [22] Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
    Lin, Hao
    Chen, Wen-Hsin
    Wu, Chen-Hsuan
    Ou, Yu-Che
    Chen, Yu-Jen
    Chen, Ying-Yi
    Lin, Yu-Han
    Fu, Hung-Chun
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 5413 - 5422
  • [23] Case report: Minimally invasive primary debulking surgery for advanced stage epithelial ovarian cancer
    Wolf, Jennifer
    Goncalves, Nicole
    Alagkiozidis, Ioannis
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [24] Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Hong Zheng
    Yu-Nong Gao
    ChineseJournalofCancerResearch, 2012, 24 (04) : 304 - 309
  • [25] Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Zheng, Hong
    Gao, Yu-Nong
    CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (04) : 304 - 309
  • [26] Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer
    Fotiou, Stelios
    Aliki, Tserkezoglou
    Petros, Zarganis
    Ioanna, Stauropoulou
    Konstantinos, Velentzas
    Vasiliki, Michalaki
    George, Creatsas
    GYNECOLOGIC ONCOLOGY, 2009, 114 (02) : 178 - 182
  • [27] Interval debulking surgery in advanced epithelial ovarian cancer
    Pecorelli, S
    Odicino, F
    Favalli, G
    BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY, 2002, 16 (04): : 573 - 583
  • [28] Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer
    Di Donato, Violante
    Caruso, Giuseppe
    Golia D'Auge, Tullio
    Perniola, Giorgia
    Palaia, Innocenza
    Tomao, Federica
    Muzii, Ludovico
    Pernazza, Angelina
    Della Rocca, Carlo
    Bogani, Giorgio
    Panici, Pierluigi Benedetti
    Giannini, Andrea
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2025, 311 (02) : 429 - 436
  • [29] Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer
    Narasimhulu, Deepa M.
    Kumar, Amanika
    Weaver, Amy L.
    McGree, Michaela E.
    Langstraat, Carrie L.
    Cliby, William A.
    GYNECOLOGIC ONCOLOGY, 2019, 155 (01) : 58 - 62
  • [30] Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease
    Ramachandran, Dhanya
    Tyrer, Jonathan P.
    Kommoss, Stefan
    DeFazio, Anna
    Riggan, Marjorie J.
    Webb, PenelopeM.
    Fasching, Peter A.
    Lambrechts, Diether
    Garcia, Maria J.
    Rodriguez-Antona, Cristina
    Goodman, Marc T.
    Modugno, Francesmary
    Moysich, Kirsten B.
    Karlan, Beth Y.
    Lester, Jenny
    Kjaer, Susanne K.
    Jensen, Allan
    Hogdall, Estrid
    Goode, Ellen L.
    Cliby, William A.
    Kumar, Amanika
    Wang, Chen
    Cunningham, Julie M.
    Winham, Stacey J.
    Monteiro, Alvaro N.
    Schildkraut, Joellen M.
    Cramer, Daniel W.
    Terry, Kathryn L.
    Titus, Linda
    Bjorge, Line
    Thomsen, Liv Cecilie Vestrheim
    Pejovic, Tanja
    Hogdall, Claus K.
    McNeish, Iain A.
    May, Taymaa
    Huntsman, David G.
    Pfisterer, Jacobus
    Canzler, Ulrich
    Park-Simon, Tjoung-Won
    Schroeder, Willibald
    Belau, Antje
    Hanker, Lars
    Harter, Philipp
    Sehouli, Jalid
    Kimmig, Rainer
    de Gregorio, Nikolaus
    Schmalfeldt, Barbara
    Baumann, Klaus
    Hilpert, Felix
    Burges, Alexander
    NPJ GENOMIC MEDICINE, 2024, 9 (01)